Drugs / AZD9793
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06795022 | Mar 2025 → Feb 2028 expected | hepatocellular carcinoma | AstraZeneca | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD9793 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06795022 ↗ |
| Route | Intravenous | “AZD9793 monotherapy administered intravenously” NCT06795022 ↗ |
| Target | GPC3 | “targets GPC3 on tumour cells” NCT06795022 ↗ |